Prognostic value of late gadolinium enhancement on CMR in patients with severe aortic valve disease: a systematic review and meta-analysis

Clinical Radiology

Volumn 73, Issue 11, 2018, Pages 983.e7-983.e14

  Chen, H ^a   Zeng, J ^a   Liu, D ^a   Yang, Q ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM;

ALL CAUSE MORTALITY; AORTIC STENOSIS; AORTIC VALVE DISEASE; AORTIC VALVE REPLACEMENT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; EMBASE; HEART MUSCLE FIBROSIS; HUMAN; MEDLINE; META ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; SYSTEMATIC REVIEW; WEB OF SCIENCE; AORTIC REGURGITATION; AORTIC VALVE; AORTIC VALVE STENOSIS; CARDIOVASCULAR DISEASE; DIAGNOSTIC IMAGING; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES;

AORTIC VALVE; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; CARDIOVASCULAR DISEASES; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; PROGNOSIS;

EID: 85050956045     PISSN: 00099260     EISSN: 1365229X     Source Type: Journal    
DOI: 10.1016/j.crad.2018.07.095     Document Type: Article

References (32)

1. Nkomo, V.T., Gardin, J.M., Skelton, T.N., et al. Burden of valvular heart diseases: a population-based study. Lancet 368:9540 (2006), 1005–1011.
2. Carabello, B.A., Introduction to aortic stenosis. Circ Res 113:2 (2013), 179–185.
3. Hein, S., Arnon, E., Kostin, S., et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107:7 (2003), 984–991.
4. Heymans, S., Schroen, B., Vermeersch, P., et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112:8 (2005), 1136–1144.
5. Villari, B., Vassalli, G., Monrad, E.S., et al. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 91:9 (1995), 2353–2358.
6. Yilmaz, A., Kindermann, I., Kindermann, M., et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 122:9 (2010), 900–909.
7. Ambale-Venkatesh, B., Lima, J.A., Cardiac MRI: a central prognostic tool in myocardial fibrosis. Nat Rev Cardiol 12:1 (2015), 18–29.
8. Debl, K., Djavidani, B., Buchner, S., et al. Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart 92:10 (2006), 1447–1451.
9. Rudolph, A., Abdel-Aty, H., Bohl, S., et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 53:3 (2009), 284–291.
10. Dweck, M.R., Joshi, S., Murigu, T., et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol 58:12 (2011), 1271–1279.
11. Barone-Rochette, G., Pierard, S., De Meester de Ravenstein, C., et al. Prognostic significance of LGE by CMR in aortic stenosis patients undergoing valve replacement. J Am Coll Cardiol 64:2 (2014), 144–154.
12. GA Wells BShea, D O'Connell, et al. Ottawa Hospital Research Institution. The Newcastle–Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.Ohri.Ca/programs/clinical_epidemiology/oxford.Asp. [Accessed 04.03.14].
13. Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21:11 (2002), 1539–1558.
14. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trial 7:3 (1986), 177–188.
15. Kuritz, S.J., Landis, J.R., Koch, G.G., A general overview of Mantel–Haenszel methods: applications and recent developments. Ann Rev Public Health 9 (1988), 123–160.
16. Azevedo, C.F., Nigri, M., Higuchi, M.L., et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 56:4 (2010), 278–287.
17. Quarto, C., Dweck, M.R., Murigu, T., et al. Late gadolinium enhancement as a potential marker of increased perioperative risk in aortic valve replacement. Interact Cardiovasc Thorac Surg 15:1 (2012), 45–50.
18. Chin, C.W.L., Everett, R.J., Kwiecinski, J., et al. Myocardial fibrosis and cardiac decompensation in aortic stenosis. JACC Cardiovasc Imaging 10:11 (2017), 1320–1333.
19. Rajesh, G.N., Thottian, J.J., Subramaniam, G., et al. Prevalence and prognostic significance of left ventricular myocardial late gadolinium enhancement in severe aortic stenosis. Indian Heart J 69:6 (2017), 742–750.
20. Lau, J., Schmid, C.H., Chalmers, T.C., Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 48:1 (1995), 45–57 discussion 59-60.
21. Harbord, R.M., Egger, M., Sterne, J.A., A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25:20 (2006), 3443–3457.
22. Flett, A.S., Sado, D.M., Quarta, G., et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging 13:10 (2012), 819–826.
23. Podlesnikar, T., Delgado, V., Bax, J.J., Cardiovascular magnetic resonance imaging to assess myocardial fibrosis in valvular heart disease. Int J Cardiovasc Imaging 34:1 (2018), 97–112.
24. Hunold, P., Schlosser, T., Vogt, F.M., et al. Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. AJR Am J Roentgenol 184:5 (2005), 1420–1426.
25. Herrmann, S., Stork, S., Niemann, M., et al. Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol 58:4 (2011), 402–412.
26. Treibel, T.A., Lopez, B., Gonzalez, A., et al. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J 39:8 (2018), 699–709.
27. Weidemann, F., Herrmann, S., Stork, S., et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 120:7 (2009), 577–584.
28. Castano, A., Narotsky, D.L., Hamid, N., et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38:38 (2017), 2879–2887.
29. Scully, P.R., Treibel, T.A., Fontana, M., et al. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol 71:4 (2018), 463–464.
30. Treibel, T.A., Fontana, M., Gilbertson, J.A., et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovas Imaging, 9(8), 2016.
31. Castano, A., Drachman, B.M., Judge, D., et al. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev 20:2 (2015), 163–178.
32. Lee, H., Park, J.B., Yoon, Y.E., et al. Noncontrast Myocardial T1 Mapping by Cardiac Magnetic Resonance Predicts Outcome in Patients With Aortic Stenosis. JACC Cardiovasc Imaging 11:7 (2018), 974–983.